Clinical significance of serum PR3-ANCA in ulcerative colitis
Not Applicable
- Conditions
- lcerative colitis
- Registration Number
- JPRN-UMIN000039174
- Lead Sponsor
- Department of Gastroenterology, Kagawa Prefectural Central Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 158
Inclusion Criteria
Not provided
Exclusion Criteria
Cases excluded were patients ages 0 to 5 or with a complication that could be serum positive for PR3-ANCA or MPO-ANCA such as autoimmune disease, chronic extraintestinal inflammatory disease, malignant tumor, or hyperthyroidism, and patients being treated or with a history of treatment with TNF alpha inhibitors, (infliximab and adalimumab), which have the potential to cause drug-induced ANCA-associated vasculitis. Also excluded from analysis were patients being treated or with a history of treatment with steroids or immunoregulators and serum PR3-ANCA levels below the detection limit.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint is the relationship between ulcerative colitis activity and serum PR3-ANCA.
- Secondary Outcome Measures
Name Time Method To evaluate the background factor and prognosis of serum PR3-ANCA positive in ulcerative colitis.